USANA Health Sciences (USNA) to Release Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA - Get Free Report) is anticipated to release its earnings data after the market closes on Tuesday, April 22nd. Analysts expect USANA Health Sciences to post earnings of $0.74 per share and revenue of $243.08 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS.Parties that wish to listen to the company's conference call can do so using this link.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Trading Up 1.3 %

USNA stock traded up $0.32 during trading on Friday, hitting $23.75. 261,409 shares of the stock traded hands, compared to its average volume of 118,466. The stock has a market cap of $448.90 million, a price-to-earnings ratio of 8.39, a P/E/G ratio of 0.93 and a beta of 1.00. USANA Health Sciences has a one year low of $23.26 and a one year high of $49.78. The company has a 50 day simple moving average of $28.44 and a 200 day simple moving average of $33.55.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 5,732 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total transaction of $186,519.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jim Brown sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the transaction, the chief executive officer now directly owns 15,716 shares in the company, valued at $463,150.52. This trade represents a 24.14 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,920 shares of company stock worth $500,285. Corporate insiders own 0.63% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.